Slater-Backed Company Acquired by Novartis

The Slater Technology Fund, Rhode Island’s oldest and most active seed-stage investment fund, applauds the team at Cadent Therapeutics, who today announced that the company has entered into an agreement to be acquired by global healthcare giant Novartis [NYSE: NVS] in a deal worth up to $770 million. 

Read More